Drug Analysis: Aranesp

Drug Analysis: Aranesp

  • January 2018 •
  • 32 pages •
  • Report ID: 5336414 •
  • Format: PDF
Drug Overview
Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia.

The drug targets the erythropoietin receptor, initiating the same pathway as native erythropoietin, and triggering increased blood production in bone marrow.